Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.
Salvatore Siena, MD
Advertisement
Articles by Salvatore Siena, MD
Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Siena on the Design of the DESTINY-CRC01 Trial in HER2+ Metastatic CRCPublished: July 7th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5